Terminated PHASE3 NCT00024167

Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer

A Prospective Randomized Phase III, Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer

Sponsor: M.D. Anderson Cancer Center

Conditions Prostate Cancer

Interventions Dexamethasone Docetaxel Doxorubicin hydrochloride Estramustine phosphate sodium Ketoconazole Prednisone Strontium chloride Sr 89 Vinblastine

Updated 6 times since 2017 Last updated: Feb 19, 2016 Started: Apr 30, 2002 Primary completion: Sep 30, 2014

Listed as NCT00024167, this PHASE3 trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by M.D. Anderson Cancer Center, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Barberton, United States , Bettendorf, United States , Billings, United States , Bozeman, United States , Butte, United States , Dallas, United States , Davenport, United States , Florence, United States , Gainesville, United States and 16 more locations